Reuters logo
BRIEF-Celyad announces initiation of the SHRINK trial
July 20, 2017 / 5:10 AM / 5 months ago

BRIEF-Celyad announces initiation of the SHRINK trial

July 20 (Reuters) - CELYAD SA:

* CELYAD ANNOUNCES INITIATION OF THE SHRINK TRIAL

* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS

* DOSE ESCALATION PART OF STUDY WILL ENROLL UP TO 18 PATIENTS

* EXTENSION PHASE WOULD ENROLL 21 ADDITIONAL PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below